Plain-English translation of NCT06679140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help people with COVID-19 who are at higher risk of becoming very sick. The medication is taken by mouth twice a day for 5 days. Half of the participants will receive the medication, and half will receive a placebo (a pill with no active medicine) to compare how well the treatment works.
Some people with COVID-19 are at higher risk of developing severe illness, especially those with certain health conditions like diabetes, heart disease, or weakened immune systems. This trial is exploring whether this medication can help prevent those at-risk patients from becoming severely ill and needing hospitalization.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to take either the medication or a placebo by mouth twice a day for 5 days. You can continue taking other standard COVID-19 treatments recommended by your doctor. The study will follow you for about 6 months total, with visits and check-ins to monitor how you are doing and whether the medication helped prevent your illness from becoming severe.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States